BridgeMD
New treatment option for Crohn Disease
Official title Evaluation of a Remote Monitoring Application in the Follow-up of Patients With Active Inflammatory Bowel Diseases
ClinicalTrials.gov ID: NCT06742385
What this study is testing
- What it's testing
- Telemonitoring is of definite theoretical interest for patients suffering from chronic diseases and could help to improve monitoring of treatment efficacy and tolerance, and hence remission and quality of life. Reimbursement is now planned in France for devices that have demonstrated a positive effect on patient intake.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- CD/UC patients with a validated diagnosis
- Patients age \> 18 years
- IBD with clinical signs of PRO2 activity leading to modification of medical treatment: introduction of a new treatment, or change of dose or addition...
- Patients willing and able to participate in the collection of data via SEMEIA App on their smartphone
- Patients agreeing to participate for 12 months
You likely can't join if
- Patients with an inability to use a smartphone and email
- Patients \< 18 years old
- Digestive surgery expected within 3 months
- Pregnancy at baseline
- Patients with an history of sub-total colectomy, coloproctectomy, digestive ostomy, extensive or multiple intestinal resections with sequelae of...
- Patients who have had recent digestive surgery (ileal resection \< 6 months) Patients with any other uncontrolled somatic or psychiatric pathology
See the full eligibility criteria
- CD/UC patients with a validated diagnosis
- Patients age \> 18 years
- IBD with clinical signs of PRO2 activity leading to modification of medical treatment: introduction of a new treatment, or change of dose or addition of a treatment (corticoids, ASA, IS, biotherapy (a 4 week induction...
- Patients willing and able to participate in the collection of data via SEMEIA App on their smartphone
- Patients agreeing to participate for 12 months
- Patients with an inability to use a smartphone and email
- Patients \< 18 years old
- Digestive surgery expected within 3 months
- Pregnancy at baseline
- Patients with an history of sub-total colectomy, coloproctectomy, digestive ostomy, extensive or multiple intestinal resections with sequelae of diarrhoea, short bowel syndrome.
- Patients who have had recent digestive surgery (ileal resection \< 6 months) Patients with any other uncontrolled somatic or psychiatric pathology
- Patients enrolled in a trial with an investigational treatment
The study team makes the final eligibility decision.
Where it's taking place
- Neuilly-sur-Seine, France, France
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Neuilly-sur-Seine, France, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.